Psychedelic Psychiatry
Advances in Clinical Medical Research and Healthcare Delivery May 31, 2022 DOI: 10.53785/2769-2779.1108 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA Psilocybin |
| Keywords | The renaissance Psychotherapist Clinical psychiatry Hallucinogen |
| Citations | 1 |
| Key findings | Psilocybin and LSD are effective for depressive disorders, and MDMA with psychotherapy is effective for PTSD. |
Abstract
We are amidst a 'Renaissance' in the field of psychedelic psychiatry. For several decades, following a period of promising research, governmental barriers and regulations halted any research into the utility of these substances in psychiatry. Over the past few decades, however, we are seeing a revival of these studies due to an abundance of positive findings as well as the need for improved psychiatric treatments. Studies have established substances such as psilocybin and LSD to be effective in treating depressive disorders, sometimes even more so than current 'gold standards'. MDMA is being recognized as a powerful tool, in conjunction with psychotherapy, for addressing PTSD symptomatology. This paper will provide a brief history of the use of psychedelics in psychiatry and discuss some of the most important recent research findings.